Development of Eye Disease Combination Therapy Halted by Regeneron, Bayer After Phase II Failures

Regeneron said today it has halted codevelopment with Bayer of a therapy combining the companies’ marketed treatment Eylea ® (aflibercept) and Regeneron’s nesvacumab—an up-to-$130 million-plus collaboration launched last year—following the combination’s failure in a pair of Phase II trials in eye disorders.The combination “did not provide sufficient differentiation to warrant Phase III development” compared with Eylea alone in the two trials, Regener